RhumbLine Advisers
CUE icon

RhumbLine Advisers’s Cue Biopharma CUE Stock Holding History

RhumbLine Advisers’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-222
Closed -$8.24K – 4230
2024
Q2 		$8.24K Sell
222
-865
-80% -$42.8K ﹤0.01% 4009
2024
Q1 		$61.6K Buy
1,087
+29
+3% +$2.05K ﹤0.01% 3577
2023
Q4 		$83.8K Buy
1,058
+11
+1% +$786 ﹤0.01% 3504
2023
Q3 		$72.2K Buy
1,047
+67
+7% +$6.54K ﹤0.01% 3558
2023
Q2 		$107K Buy
+980
New +$115K ﹤0.01% 3501
2022
Q2 		– Sell
-1,059
Closed -$155K – 3127
2022
Q1 		$155K Sell
1,059
-1
-0.1% -$212 ﹤0.01% 2812
2021
Q4 		$360K Sell
1,060
-20
-2% -$7.73K ﹤0.01% 2640
2021
Q3 		$472K Buy
1,080
+46
+4% +$16K ﹤0.01% 2572
2021
Q2 		$361K Sell
1,034
-69
-6% -$26.7K ﹤0.01% 2714
2021
Q1 		$404K Sell
1,103
-61
-5% -$25.1K ﹤0.01% 2582
2020
Q4 		$437K Buy
1,164
+25
+2% +$9.99K ﹤0.01% 2493
2020
Q3 		$514K Sell
1,139
-57
-5% -$32.8K ﹤0.01% 2280
2020
Q2 		$880K Buy
1,196
+375
+46% +$272K ﹤0.01% 2096
2020
Q1 		$350K Buy
821
+14
+2% +$6.79K ﹤0.01% 2330
2019
Q4 		$384K Buy
807
+19
+2% +$5.97K ﹤0.01% 2485
2019
Q3 		$199K Buy
788
+8
+1% +$1.92K ﹤0.01% 2751
2019
Q2 		$210K Buy
780
+20
+3% +$4.97K ﹤0.01% 2772
2019
Q1 		$176K Hold
760
– – ﹤0.01% 2774
2018
Q4 		$107K Buy
760
+258
+51% +$46.8K ﹤0.01% 2877
2018
Q3 		$136K Sell
502
-27
-5% -$7.8K ﹤0.01% 2820
2018
Q2 		$188K Buy
+529
New +$210K ﹤0.01% 2750

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

RhumbLine Advisers's CUE Position: Q3 2024 in Review

RhumbLine Advisers sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 222 shares — an estimated $8.24K sold.

RhumbLine Advisers first reported a position in CUE in Q2 2018 and held it in 21 quarters. The position peaked at $880K in Q2 2020. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • RhumbLine Advisers reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 222 Cue Biopharma shares in Q3 2024, an estimated $8.24K.
  • RhumbLine Advisers first reported a position in Cue Biopharma in Q2 2018 and held it in 21 quarters.
  • RhumbLine Advisers's Cue Biopharma position peaked at $880K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.